Skip to main content

8-K

Rallybio Corp (RLYB)

8-K 2025-05-16 For: 2025-05-13
View Original
Added on April 07, 2026
View as plain text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________________________________________________

FORM 8-K

______________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2025

______________________________________________________

RALLYBIO CORPORATION

(Exact name of Registrant as Specified in Its Charter)

______________________________________________________

Delaware 001-40693 85-1083789
(State or Other Jurisdiction<br>of Incorporation) (Commission File Number) (IRS Employer<br>Identification No.)
234 Church Street, Suite 1020 New Haven, Connecticut 06510
(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: 203 859-3820

(Former Name or Former Address, if Changed Since Last Report)

______________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading<br>Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share RLYB NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.07. Submission of Matters to a Vote of Security Holders.

Rallybio Corporation (Rallybio) held its annual meeting of shareholders on May 13, 2025.

The results of the matters voted on by the shareholders are set forth below.

  1. The following nominees were elected to the Board of Directors as Class I directors for terms expiring at the 2028 annual meeting of shareholders.
For Against Abstentions/Broker Non-Votes
Martin W. Mackay 23,833,701 3,132,991 7,708,200
Paula Soteropoulos 23,812,816 3,153,701 7,708,375
  1. The shareholders ratified the appointment of Deloitte and Touche LLP as the independent registered public accounting firm for Rallybio for the fiscal year ending December 31, 2025.
For Against Abstentions/Broker Non-Votes
34,632,324 40,810 1,758

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

RALLYBIO CORPORATION
Date: May 16, 2025 By: /s/ Jonathan I. Lieber
Jonathan I. Lieber<br>Chief Financial Officer and Treasurer